Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
Arthritis Rheumatol. 2023;75(8):1370–1380 doi: 10.1002/art.42519
Phase IIb study of brepocitinib in patients with PsA concludes that treatment with brepocitinib 30 mg and 60 mg QD, was superior to placebo at reducing signs and symptoms of PsA and was well-tolerated over 52 weeks.
Despite a variety of treatment options, PsA treatment goals of decreasing disease activity, improving HRQoL and function, and preventing structural damage and complications, remain unmet needs.
To help address this, Mease, et al. assessed efficacy and safety of oral brepocitinib in participants with moderate-to-severe PsA for up to 52 weeks.
Keywords:
